SCALE-C: Strategies for hepatitis C testing and treatment in Aboriginal communities that Lead to Elimination

在澳大利亚所有可识别的人口中，原住民中丙型肝炎的感染率是最高的。高效、直接作用的抗病毒(DAA)疗法，并于2016年在公共广播公司上市，使澳大利亚的丙型肝炎临床管理发生了革命性的变化。C级研究将评估已建立的测试和治疗模式，以在四个土著社区内迅速扩大DAA，以确定对社区流行率和正在进行的传播的影响。

Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.